Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis

Annals of Tropical Medicine and Parasitology

Volumn 97, Issue 3, 2003, Pages 259-268

  Cauchetier, E ^a,d   Paul, M ^a   Rivollet, D ^a   Fessi, H ^b   Astier, A ^a,c   Deniau, M ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d CENTRE HOSPITALIER VICTOR DUPOUY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONE; ATOVAQUONE; BENZYL BENZOATE; CREMOPHOR; DIMETHYL SULFOXIDE; NANOCAPSULE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYLACTIDE; SYNPERONIC; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENCAPSULATION; EVALUATION; LEISHMANIA DONOVANI; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PROMASTIGOTE; RODENT; SPLEEN WEIGHT; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; ATOVAQUONE; BIOCOMPATIBLE MATERIALS; CAPSULES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIVER; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; NAPHTHOQUINONES; POLYESTERS;

AMBYSTOMA TIGRINUM STEBBENSI VIRUS; ANIMALIA; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; MURINAE; PROTOZOA; RODENTIA;

EID: 0038147016     PISSN: 00034983     EISSN: None     Source Type: Journal    
DOI: 10.1179/000349803235001840     Document Type: Article

References (38)

1. Anon. (1985). Guiding Principles for Biomedical Research. Geneva: Council for International Organization of Medical Sciences.
2. Belbella, A., Vauthier, C., Fessi, H., Devissaguet, J. P. & Puisieux, F. (1996). In vitro degradation of nanospheres from poly(D,L-lactides) of different molecular weights and polydispersities. International Journal of Pharmaceutics, 129, 95-102.
3. Berman, J. D., Waddell, D. & Hanson, B. D. (1985). Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrobial Agents and Chemotherapy, 27, 916-920.
4. Bradley, D. J. & Kirkley, J. (1977). Regulation of Leishmania populations within the host. The variable course of Leishmania donovani infections in mice. Clinical and Experimental Immunology, 30, 119-129.
5. Bryceson, A. D. M. (1987). Therapy in man. In The Leishmaniases in Biology and Medicine, Vol. 2, eds Peters, W. & Killick-Kendrick, R. pp. 847-907. London: Academic Press.
6. Cauchetier, E., Fessi, H., Boulard, Y., Deniau, M., Astier, A. & Paul, M. (1999). Preparation and physicochemical characterization of atovaquone-loaded liposomes. Drug Development Research, 47, 155-161.
7. Cauchetier, E., Paul, M., Rivollet, D., Fessi, H., Astier, A. & Deniau, M. (2000). Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis. International Journal for Parasitology, 30, 777-783.
8. Cauchetier, E., Deniau, M., Fessi, H., Astier, A. & Paul, M. (2003). Atovaquone-loaded nanocapsules: influence of the nature of the polymer on their in vitro characteristics. International Journal of Pharmaceutics, 250, 273-281.
9. Chonn, A. & Cullis, P. R. (1995). Recent advances in liposomal drug-delivery systems. Current Opinion in Biotechnology, 6, 698-708.
10. Croft, S. L., Hogg, J., Gutteridge, W. E., Hudson, A. T. & Randall, A. W. (1992). The activity of hydroxynaphtoquinones against Leishmania donovani. Journal of Antimicrobial Chemotherapy, 30, 827-832.
11. Davidson, R. N., di Martino, L., Gradoni, L., Giacchino, R., Russo, R., Gaeta, G. B., Pempinello, R., Scott, S., Raimondi, F., Cascio, A., Prestileo, T., Caldeira, L., Wilkinson, R. J. & Bryceson, A. D. M. (1994). Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Quarterly Journal of Medicine, 87, 75-81.
12. Desjeux, P., Piot, B., O'Neil, K. & Meert, J. P. (2001). Co-infections of Leishmania/HIV in south Europe. Médecine Tropicale, 61, 187-193.
13. Di Giorgio, C., Faraut-Gambarelli, F., Imbert, A., Minodier, P., Gasquet, M. & Dumon, H. (1999). Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis. Journal of Antimicrobial Chemotherapy, 44, 71-76.
14. Durand, R., Paul, M., Rivollet, D., Fessi, H., Houin, R., Astier, A. & Deniau, M. (1997a). Activity of pentamidine-loaded poly(D,L-lactide) nanoparticles against Leishmania infantum in a murine model. Parasite, 4, 331-336.
15. Durand, R., Paul, M., Rivollet, D., Houin, R., Astier, A. & Deniau, M. (1997b). Activity of pentamidine loaded methacrylate nanoparticles against Leishmania infantum in a mouse model. International Journal of Parasitology, 27, 1361-1367.
16. Faraut-Gambarelli, F., Piarroux, R., Deniau, M., Giusiano, B., Marty, P., Michel, G., Faugere, B. & Dumon, H. (1997). In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 41, 827-830.
17. Fernandez-Urrusuno, R., Fattal, E., Rodrigues Jr, J. M., Feger, J., Bedossa, P. & Couvreur, P. (1996). Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. Journal of Biomedical Materials Research, 31, 401-408.
18. Gordeliy, V. I., Kiselev, M. A., Lesieur, P., Pole, A. V. & Teixeira, J. (1998). Lipid membrane structure and interactions in dimethyl sulfoxide/water mixtures. Biophysical Journal, 75, 2343-2351.
19. Gradoni, L., Bryceson, A. & Desjeux, P. (1995). Treatment of Mediterranean visceral leishmaniasis. Bulletin of the World Health Organization, 73, 191-197.
20. Haile, L. G. & Flaherty, J. F. (1993). Atovaquone: a review. Annals of Pharmacotherapy, 27, 1488-1494.
21. Jernigan, J. A., Pearson, R. D., Rogers, M. D. & Petri, W. A. (1996). In vitro activity of atovaquone against Leishmania chagasi promastigotes. Antimicrobial Agents and Chemotherapy, 40, 1064.
22. Kedzierewicz, F., Thouvenot, P., Monot, I., Hoffman, M. & Maincent, P. (1998). Influence of different physicochemical conditions on the release of indium oxine from nanocapsules. Journal of Biomedical Materials Research, 39, 588-593.
23. Levasseur, L. M., Slocum, H. K., Rustum, Y. M. & Greco, W. R. (1998). Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Research, 58, 5749-5761.
24. Losa, C., Marchal-Heussler, L., Orallo, F., Vila Jato, J. L. & Alonso, M. J. (1993). Design of new formulations for topical ocular administration: polymeric nanocapsules containing metiprolol. Pharmaceutical Research, 10, 80-87.
25. Marchais, H., Benali, S., Irache, J. M., Tharasse-Bloch, C., Lafont, O. & Orechioni, A. M. (1998). Entrapment efficiency and initial release of phenylbutazone from nanocapsules prepared from different polyesters. Drug Development and Industrial Pharmacy, 24, 883-888.
26. Mauduit, J. & Vert, M. (1993). Les polymėres à base d'acides lactiques et glycoliques et la délivrance contrôlée des principes actifs. STP Pharma Sciences, 3, 197-212.
27. Meyerhoff, A. (1999). U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clinical Infectious Diseases, 28, 42-48.
28. Morishige, K., Aji, T., Ishii, A., Yasuda, T. & Wataya, Y. (1995). Leishmania donovani: pilot study for evaluation of therapeutic effects of inosine analogs against amastigotes in vitro and in vivo. Experimental Parasitology, 80, 665-671.
29. Murray, H. W. & Hariprashad, J. (1996). Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 40, 586-587.
30. Paul, M., Durand, R., Fessi H., Rivollet, D., Houin, R., Astier, A. & Deniau, M. (1997). Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Antimicrobial Agents and Chemotherapy, 41, 1731-1734.
31. Rodrigues, J. M., Croft, S. L., Fessi, H., Bories, C. & Devissaguet, J. P. (1994). The activity and ultra-structural localization of primaquine-loaded poly(D,L-lactide) nanoparticles in Leishmania donovani infected mice. Tropical Medicine and Parasitology, 45, 223-228.
32. Russo, R., Nigro, L. C., Minniti, S., Montineri, A., Gradoni, L., Caldeira, L. & Davidson, R. N. (1996). Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). Journal of Infection, 32, 133-137.
33. Santos Magalhaes, N. S., Fessi, H., Puisieux, F., Benita, S. & Seiller, M. (1995). An in vitro release kinetic examination and comparative evaluation between submicron emulsion and polylactic acid nanocapsules of clofibride. Journal of Microencapsulation, 12, 195-205.
34. Sordet, F., Amjaud, Y., Fessi, H. & Derouin, F. (1998). Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis. Parasite, 5, 223-229.
35. Stauber, L. A., Franchino, E. M. & Grun, J. (1958). An eight-day method for screening compounds against Leishmania donovani in golden hamsters. Journal of Protozoology, 5, 269-273.
36. Trotter, E. R., Peters, W. & Robinson, B. L. (1980). The experimental chemotherapy of leishmaniasis. IV. The development of a rodent model for visceral infection. Annals of Tropical Medicine and Parasitology, 74, 127-138.
37. Venier-Julienne, M. C., Vouldoukis, L., Monjour, L. & Benoit, J. P. (1995). In vitro study of the antileishmanial activity of biodegradable nanoparticles. Drug Targeting, 3, 23-29.
38. Yu, Z. W. & Quinn, P. J. (1998). The modulation of membrane structure and stability by dimethyl sulfoxide. Molecular Membrane Biology, 15, 59-68.